My ePortfolio Register   

FDA approves liposome-encapsulated daunorubicin-cytarabine for poor prognosis AML

The U.S. Food and Drug Administration has granted regular approval to a liposome-encapsulated combination of daunorubicin and cytarabine (VYXEOS, Jazz Pharmaceuticals, Inc.) for the treatment of adults with newly-diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC), two types of AML having a poor prognosis.

This is the first FDA-approved treatment specifically for patients with t-AML or AML-MRC.

Approval was based on data from Study CLTR0310-301 (NCT01696084), a randomised (1:1), multicenter, open-label, active-controlled trial comparing the liposomal delivery to a standard combination of daunorubicin and cytarabine (7 3) in 309 patients 60-75 years of age with newly-diagnosed t-AML or AML-MRC.

The liposomal formulation demonstrated an estimated median overall survival of 9.6 months compared with 5.9 months for the 7 3 control (hazard ratio 0.69; 95% CI: 0.52, 0.90; p=0.005).

The most common adverse reactions occurring in greater than 25% of patients were hemorrhage events, febrile neutropenia, rash, edema, nausea, mucositis, diarrhea, constipation, musculoskeletal pain, fatigue, abdominal pain, dyspnea, headache, cough, decreased appetite, arrhythmia, pneumonia, bacteremia, chills, sleep disorders and vomiting.

FDA previously granted Breakthrough Therapy and Orphan Drug designations to the combination product for this indication, as well as priority review.

FDA approval took place two months ahead of the goal date.

Each vial contains 44 mg daunorubicin and 100 mg cytarabine encapsulated together in liposomes.

The volume required for each dose is calculated based on the daunorubicin dose (mg/m2) using body surface area.

Since this is a fixed-dose combination, and dosing based on the daunorubicin component, the corresponding cytarabine dose is included and does not need to be calculated.

For the first induction cycle, the recommended dose is (daunorubicin 44 mg/m2 and cytarabine 100 mg/m2) liposome via intravenous infusion over 90 minutes on days 1, 3, and 5.

If needed, the same dose is administered on days 1 and 3 of second induction.

The recommended dose for each cycle of consolidation therapy is (daunorubicin 29 mg/m2 and cytarabine 65 mg/m2) liposome via intravenous infusion over 90 minutes on days 1 and 3.

Source: FDA

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence